UY26801A1 - Composición de vacuna - Google Patents
Composición de vacunaInfo
- Publication number
- UY26801A1 UY26801A1 UY26801A UY26801A UY26801A1 UY 26801 A1 UY26801 A1 UY 26801A1 UY 26801 A UY26801 A UY 26801A UY 26801 A UY26801 A UY 26801A UY 26801 A1 UY26801 A1 UY 26801A1
- Authority
- UY
- Uruguay
- Prior art keywords
- vaccine composition
- influenzae
- conjugate
- capsular polysaccharide
- pertussis
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title 1
- 150000004676 glycans Chemical class 0.000 abstract 5
- 229920001282 polysaccharide Polymers 0.000 abstract 5
- 239000005017 polysaccharide Substances 0.000 abstract 5
- 241000606768 Haemophilus influenzae Species 0.000 abstract 3
- 201000005702 Pertussis Diseases 0.000 abstract 2
- 210000003850 cellular structure Anatomy 0.000 abstract 2
- 229960003983 diphtheria toxoid Drugs 0.000 abstract 2
- 229940031348 multivalent vaccine Drugs 0.000 abstract 2
- 229960000814 tetanus toxoid Drugs 0.000 abstract 2
- 201000009906 Meningitis Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Composición de vacuna multivalente comprendiendo un conjugado del polisacárido capsular de H. influenzae b no absorbido sobre sal coadyuvante de aluminio, y dos o más polisacáridos bacterianos adicionales. Componente de células enteras de pertussis, toxoide del tétanos, toxoide de las difteria, antígeno de superficie de hepatitis B, conjugado del polisacárido capsular de H. Influenzae b, y un conjugado de un polisacárido capsular de N. Meningitis de tipo A o C (o ambos). Composición de vacuna multivalente comprendiendo componente de células enteras de pertussis, toxoide del tétano, toxoide de la difteria y una dosis baja de un conjunto del polisacárido capsular de H. Influenzae.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0015999.6A GB0015999D0 (en) | 2000-06-29 | 2000-06-29 | Novel compounds |
GBGB0108364.1A GB0108364D0 (en) | 2001-04-03 | 2001-04-03 | Vaccine composition |
GB0108363A GB0108363D0 (en) | 2001-04-03 | 2001-04-03 | Vaccine composition |
Publications (1)
Publication Number | Publication Date |
---|---|
UY26801A1 true UY26801A1 (es) | 2002-01-31 |
Family
ID=27255788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY26801A UY26801A1 (es) | 2000-06-29 | 2001-06-27 | Composición de vacuna |
Country Status (35)
Country | Link |
---|---|
US (2) | US20030180316A1 (es) |
EP (4) | EP1296715B2 (es) |
JP (2) | JP4870895B2 (es) |
KR (3) | KR100837917B1 (es) |
CN (2) | CN101708333B (es) |
AP (1) | AP1695A (es) |
AT (1) | ATE534402T1 (es) |
AU (2) | AU2001281895C1 (es) |
BG (2) | BG66238B1 (es) |
BR (2) | BRPI0112057B8 (es) |
CA (2) | CA2783274C (es) |
CY (2) | CY1112280T1 (es) |
CZ (1) | CZ20024224A3 (es) |
DK (2) | DK1296715T4 (es) |
DZ (1) | DZ3399A1 (es) |
EA (2) | EA011480B1 (es) |
EG (1) | EG24742A (es) |
ES (2) | ES2385100T3 (es) |
HK (1) | HK1055244A1 (es) |
HU (3) | HU227613B1 (es) |
IL (2) | IL153506A0 (es) |
MA (1) | MA25824A1 (es) |
MX (1) | MXPA03000198A (es) |
MY (1) | MY133981A (es) |
NO (1) | NO332495B1 (es) |
NZ (1) | NZ523319A (es) |
OA (1) | OA12302A (es) |
PE (1) | PE20020126A1 (es) |
PL (2) | PL210015B1 (es) |
PT (2) | PT1296715E (es) |
SI (2) | SI1946769T1 (es) |
SK (1) | SK288007B6 (es) |
UA (2) | UA85853C2 (es) |
UY (1) | UY26801A1 (es) |
WO (1) | WO2002000249A2 (es) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4540795B2 (ja) * | 2000-03-10 | 2010-09-08 | 一般財団法人阪大微生物病研究会 | 生ワクチンの細胞性免疫活性を不活化ワクチンにも起こさせる方法、及びこれより得られる混合ワクチン |
GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
MY133981A (en) | 2000-06-29 | 2007-11-30 | Smithkline Beecham Biologicals S A | Vaccine composition |
CN100556459C (zh) | 2001-01-23 | 2009-11-04 | 安万特巴斯德公司 | 多价脑膜炎球菌多糖-蛋白质缀合疫苗 |
AU2007200116A1 (en) * | 2001-04-03 | 2007-02-01 | Glaxosmithkline Biologicals S.A. | Vaccine composition |
DE60236864D1 (de) | 2001-05-31 | 2010-08-12 | Novartis Vaccines & Diagnostic | Chimere alphavirus-replikon-partikel |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0302218D0 (en) * | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
EP1506007B1 (en) * | 2002-05-14 | 2011-06-22 | Novartis Vaccines and Diagnostics S.r.l. | Mucosal combination vaccines for bacterial meningitis |
MXPA04011249A (es) | 2002-05-14 | 2005-06-06 | Chiron Srl | Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos. |
JP4697706B2 (ja) | 2002-10-11 | 2011-06-08 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン |
AR041880A1 (es) * | 2002-11-01 | 2005-06-01 | Glaxosmithkline Biolog Sa | Composicion inmunogena |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
CA3042073C (en) | 2003-01-30 | 2022-09-13 | Novartis Vaccines And Diagnostics S.R.L. | Injectable vaccines against multiple meningococcal serogroups |
JP2006516609A (ja) * | 2003-01-30 | 2006-07-06 | カイロン ソチエタ ア レスポンサビリタ リミタータ | 粘膜髄膜炎菌性ワクチン |
BRPI0410423A (pt) | 2003-05-07 | 2006-06-06 | Sanofi Pasteur Inc | processo de imunogenicidade melhorada para vacinação meningocócica |
GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
EP2364725A3 (en) * | 2003-06-23 | 2012-05-09 | Sanofi Pasteur Inc. | Immunization method against neisseria meningitidis serogroups a and c |
JP4738339B2 (ja) * | 2003-10-02 | 2011-08-03 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 複数の髄膜炎菌血清群についての液体ワクチン |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
CU23404A1 (es) * | 2003-11-19 | 2009-08-04 | Ct Ingenieria Genetica Biotech | Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes |
GB0405787D0 (en) | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
EP1740217B1 (en) | 2004-04-30 | 2011-06-15 | Novartis Vaccines and Diagnostics S.r.l. | Meningococcal conjugate vaccination |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0409745D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
GB0502096D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7709001B2 (en) * | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
KR102220506B1 (ko) | 2005-04-08 | 2021-03-02 | 와이어쓰 엘엘씨 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
SG175456A1 (en) | 2005-04-18 | 2011-11-28 | Novartis Vaccines & Diagnostic | Expressing hepatitis b virus surface antigen for vaccine preparation |
GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
CN103083657B (zh) * | 2005-06-27 | 2016-06-08 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
CN1709505B (zh) * | 2005-07-13 | 2010-06-16 | 北京绿竹生物制药有限公司 | 多价细菌荚膜多糖-蛋白质结合物联合疫苗 |
WO2007026249A2 (en) | 2005-09-01 | 2007-03-08 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Multiple vaccination including serogroup c meningococcus |
CN101355960A (zh) | 2005-10-18 | 2009-01-28 | 诺华疫苗和诊断公司 | 使用α病毒复制子颗粒进行粘膜和全身免疫 |
GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
KR101515078B1 (ko) * | 2005-12-22 | 2015-04-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
GB0607088D0 (en) * | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
EP1940462A2 (en) * | 2005-12-23 | 2008-07-09 | GlaxoSmithKline Biologicals S.A. | Conjugate vaccines |
ES2809167T3 (es) * | 2006-01-17 | 2021-03-03 | Forsgren Arne | Una novedosa proteína de Haemophilus influenzae expuesta en la superficie (proteína E; pE) |
TR201807355T4 (tr) | 2006-03-22 | 2018-06-21 | Glaxosmithkline Biologicals Sa | Meningokokkal konjugatlarla immünizasyon rejimleri. |
TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
EP1872791A1 (en) | 2006-06-30 | 2008-01-02 | Institut Pasteur | Use of bacterial polysaccharides for biofilm inhibition |
CA2662064A1 (en) | 2006-09-07 | 2008-03-13 | Glaxosmithkline Biologicals S.A. | Method of producing a combination polivirus vaccine |
BRPI0810778A2 (pt) | 2007-05-02 | 2011-09-13 | Glaxosmithkline Biolog Sa | kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo |
ES2555786T3 (es) | 2007-06-04 | 2016-01-08 | Glaxosmithkline Biologicals Sa | Formulación de vacunas contra la meningitis |
ES2552366T3 (es) | 2007-06-26 | 2015-11-27 | Glaxosmithkline Biologicals S.A. | Vacuna que comprende conjugados de polisacárido capsular de Streptococcus pneumoniae |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
RU2477145C2 (ru) * | 2008-05-30 | 2013-03-10 | ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ | Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения |
PE20100365A1 (es) | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion |
GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
PT2575870T (pt) * | 2010-06-04 | 2017-02-10 | Wyeth Llc | Formulações de vacinas |
CN103260642B (zh) * | 2010-12-14 | 2018-03-16 | 葛兰素史密丝克莱恩生物有限公司 | 分枝杆菌抗原组合物 |
CN103442730B (zh) | 2011-01-05 | 2016-08-17 | 巴拉特生物技术国际有限公司 | 组合七价疫苗 |
GB201105981D0 (en) | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
DE102011122891B4 (de) | 2011-11-11 | 2014-12-24 | Novartis Ag | Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen |
GB2495341B (en) | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
DE102011118371B4 (de) | 2011-11-11 | 2014-02-13 | Novartis Ag | Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung |
EP2592137A1 (en) | 2011-11-11 | 2013-05-15 | Novartis AG | Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use |
SI2809349T1 (sl) * | 2012-01-30 | 2019-03-29 | Serum Institute Of India Private Limited | Imunogeni sestavek |
EP2822584A1 (en) * | 2012-03-08 | 2015-01-14 | Novartis AG | Combination vaccines with tlr4 agonists |
JP2015525794A (ja) | 2012-08-06 | 2015-09-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 乳児においてrsv及び百日咳菌に対する免疫応答を惹起するための方法 |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
JP6440619B2 (ja) | 2012-10-12 | 2018-12-19 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 混合ワクチン用の架橋されていない無細胞百日咳抗原 |
EA201590491A1 (ru) * | 2012-10-17 | 2016-01-29 | Глаксосмитклайн Байолоджикалс С.А. | Иммуногенная композиция |
KR20140075201A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
PE20151720A1 (es) | 2013-03-08 | 2015-12-10 | Crucell Holland Bv | Vacuna acelular contra pertussis |
RU2016103771A (ru) * | 2013-07-07 | 2017-08-11 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Синтетические вакцины против streptococcus pneumoniae 1-го типа |
EP3492097A1 (en) | 2013-08-05 | 2019-06-05 | GlaxoSmithKline Biologicals S.A. | Combination immunogenic compositions |
US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
RU2626532C2 (ru) * | 2015-01-16 | 2017-07-28 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации | Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в |
MX2017010705A (es) * | 2015-02-19 | 2017-12-04 | Pfizer | Composiciones de neisseria meningitidis y metodos de la misma. |
CA3031797A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
MX2019001342A (es) | 2016-08-05 | 2019-07-04 | Sanofi Pasteur Inc | Composicion de conjugado de proteina-polisacarido de neumococo multivalente. |
CN109890413B (zh) | 2016-09-02 | 2024-04-16 | 赛诺菲巴斯德股份有限公司 | 脑膜炎奈瑟氏菌疫苗 |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
SG11202005255PA (en) | 2017-12-06 | 2020-07-29 | Merck Sharp & Dohme | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
CA3089007A1 (en) | 2018-02-05 | 2019-08-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
WO2019152921A1 (en) | 2018-02-05 | 2019-08-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
JP2021522213A (ja) | 2018-04-18 | 2021-08-30 | エスケー バイオサイエンス カンパニー リミテッド | ストレプトコッカス・ニューモニエ莢膜多糖類及びその免疫原性接合体 |
US11896656B2 (en) * | 2018-04-30 | 2024-02-13 | Merck Sharp & Dohme Llc | Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide |
KR20200005458A (ko) | 2018-07-06 | 2020-01-15 | 주식회사 유바이오로직스 | 다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 약학 조성물 |
KR20210092224A (ko) * | 2018-11-10 | 2021-07-23 | 브하라트 바이오테크 인터내셔날 리미티드 | 다가 당접합체 면역원성 조성물 |
MX2021007496A (es) | 2018-12-19 | 2021-08-05 | Merck Sharp & Dohme Llc | Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y sus metodos de uso. |
GB2599572B (en) | 2019-05-20 | 2023-09-20 | Soligenix Inc | Compositions and methods of manufacturing trivalent filovirus vaccines |
CN111821432B (zh) * | 2020-08-05 | 2022-10-18 | 北京智飞绿竹生物制药有限公司 | 一种多价肺炎球菌结合疫苗 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057685A (en) * | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
EP0027888B1 (en) * | 1979-09-21 | 1986-04-16 | Hitachi, Ltd. | Semiconductor switch |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4673574A (en) * | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4459286A (en) * | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
JPS6061288A (ja) * | 1983-09-13 | 1985-04-09 | Fuji Photo Film Co Ltd | 感熱記録材料 |
US4808700A (en) * | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
GB8516442D0 (en) | 1985-06-28 | 1985-07-31 | Wellcome Found | Cloned antigen |
GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
GB8914122D0 (en) | 1989-06-20 | 1989-08-09 | Wellcome Found | Polypeptide expression |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
EP0643559B1 (en) | 1992-05-06 | 1999-04-14 | The President And Fellows Of Harvard College | Diphtheria toxin receptor-binding region |
EP2289548A3 (en) | 1992-05-23 | 2012-08-08 | GlaxoSmithKline Biologicals S.A. | Combined vaccines comprising hepatitis B surface antigen and other antigens |
JP3428646B2 (ja) | 1992-06-18 | 2003-07-22 | プレジデント アンド フェローズ オブ ハーバードカレッジ | ジフテリア毒素ワクチン |
SG49909A1 (en) | 1992-06-25 | 1998-06-15 | Smithkline Beecham Biolog | Vaccine composition containing adjuvants |
EP0594950B1 (en) * | 1992-10-27 | 1999-01-27 | American Cyanamid Company | Combination pediatric vaccine with enhanced immunogenicity of each vaccine component |
US5849301A (en) * | 1993-09-22 | 1998-12-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents |
AU678613B2 (en) | 1993-09-22 | 1997-06-05 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5869058A (en) * | 1994-05-25 | 1999-02-09 | Yeda Research And Development Co. Ltd. | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines |
US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
GB9422096D0 (en) * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
WO1997000697A1 (en) * | 1995-06-23 | 1997-01-09 | Smithkline Beecham Biologicals S.A. | A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5997881A (en) | 1995-11-22 | 1999-12-07 | University Of Maryland, Baltimore | Method of making non-pyrogenic lipopolysaccharide or A |
WO1998033923A1 (en) | 1997-01-30 | 1998-08-06 | Imperial College Of Science, Technology & Medicine | MUTANT msbB or htrB GENES |
EP1028750B1 (en) * | 1997-09-15 | 2006-02-01 | Sanofi Pasteur MSD | Method for preparing multivalent vaccines |
US5965714A (en) * | 1997-10-02 | 1999-10-12 | Connaught Laboratories, Inc. | Method for the covalent attachment of polysaccharides to protein molecules |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
GB9806456D0 (en) * | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
US6146902A (en) * | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
GB9925559D0 (en) | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
FR2806304B1 (fr) * | 2000-03-17 | 2002-05-10 | Aventis Pasteur | Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie |
MY133981A (en) | 2000-06-29 | 2007-11-30 | Smithkline Beecham Biologicals S A | Vaccine composition |
GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
AU2003257003A1 (en) * | 2002-07-30 | 2004-02-16 | Baxter Healthcare S.A. | Chimeric multivalent polysaccharide conjugate vaccines |
GB0405787D0 (en) * | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
GB0500787D0 (en) * | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0428394D0 (en) * | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
GB0502095D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
CN103083657B (zh) * | 2005-06-27 | 2016-06-08 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
KR101515078B1 (ko) * | 2005-12-22 | 2015-04-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
GB0607088D0 (en) * | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
EP1940462A2 (en) * | 2005-12-23 | 2008-07-09 | GlaxoSmithKline Biologicals S.A. | Conjugate vaccines |
GB0700136D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
GB0700135D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Vaccine |
US8885224B2 (en) * | 2007-03-14 | 2014-11-11 | Konica Minolta Business Technologies, Inc. | Information embedding method, its program and information embedding device |
BRPI0810778A2 (pt) * | 2007-05-02 | 2011-09-13 | Glaxosmithkline Biolog Sa | kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo |
ES2555786T3 (es) * | 2007-06-04 | 2016-01-08 | Glaxosmithkline Biologicals Sa | Formulación de vacunas contra la meningitis |
ES2552366T3 (es) * | 2007-06-26 | 2015-11-27 | Glaxosmithkline Biologicals S.A. | Vacuna que comprende conjugados de polisacárido capsular de Streptococcus pneumoniae |
-
2001
- 2001-06-27 MY MYPI20013027 patent/MY133981A/en unknown
- 2001-06-27 SK SK1843-2002A patent/SK288007B6/sk not_active IP Right Cessation
- 2001-06-27 PL PL360265A patent/PL210015B1/pl unknown
- 2001-06-27 AP APAP/P/2002/002700A patent/AP1695A/en active
- 2001-06-27 BR BRPI0112057A patent/BRPI0112057B8/pt not_active IP Right Cessation
- 2001-06-27 PT PT01960390T patent/PT1296715E/pt unknown
- 2001-06-27 AU AU2001281895A patent/AU2001281895C1/en active Active
- 2001-06-27 SI SI200131012T patent/SI1946769T1/sl unknown
- 2001-06-27 ES ES07116669T patent/ES2385100T3/es not_active Expired - Lifetime
- 2001-06-27 CA CA2783274A patent/CA2783274C/en not_active Expired - Lifetime
- 2001-06-27 UY UY26801A patent/UY26801A1/es not_active IP Right Cessation
- 2001-06-27 OA OA1200200395A patent/OA12302A/en unknown
- 2001-06-27 HU HU1000594A patent/HU227613B1/hu unknown
- 2001-06-27 EG EG20010701A patent/EG24742A/xx active
- 2001-06-27 DK DK01960390.1T patent/DK1296715T4/en active
- 2001-06-27 KR KR1020027017928A patent/KR100837917B1/ko active IP Right Grant
- 2001-06-27 SI SI200131007T patent/SI1296715T2/sl unknown
- 2001-06-27 MX MXPA03000198A patent/MXPA03000198A/es active IP Right Grant
- 2001-06-27 IL IL15350601A patent/IL153506A0/xx unknown
- 2001-06-27 CN CN200910174266.7A patent/CN101708333B/zh not_active Expired - Lifetime
- 2001-06-27 HU HU0301413A patent/HU228384B1/hu unknown
- 2001-06-27 NZ NZ523319A patent/NZ523319A/en not_active IP Right Cessation
- 2001-06-27 DK DK07116669.8T patent/DK1946769T3/da active
- 2001-06-27 EA EA200501070A patent/EA011480B1/ru not_active IP Right Cessation
- 2001-06-27 EP EP01960390.1A patent/EP1296715B2/en not_active Expired - Lifetime
- 2001-06-27 ES ES01960390.1T patent/ES2375704T5/es not_active Expired - Lifetime
- 2001-06-27 KR KR1020087013186A patent/KR100898845B1/ko active IP Right Grant
- 2001-06-27 EP EP10178451A patent/EP2277541A1/en not_active Withdrawn
- 2001-06-27 BR BR122012003821A patent/BR122012003821B8/pt not_active IP Right Cessation
- 2001-06-27 HU HU1000593A patent/HU227893B1/hu unknown
- 2001-06-27 CN CN018146198A patent/CN1449293B/zh not_active Expired - Lifetime
- 2001-06-27 AT AT01960390T patent/ATE534402T1/de active
- 2001-06-27 UA UAA200604994A patent/UA85853C2/uk unknown
- 2001-06-27 EP EP07116669A patent/EP1946769B1/en not_active Expired - Lifetime
- 2001-06-27 PT PT07116669T patent/PT1946769E/pt unknown
- 2001-06-27 JP JP2002505030A patent/JP4870895B2/ja not_active Expired - Lifetime
- 2001-06-27 AU AU8189501A patent/AU8189501A/xx active Pending
- 2001-06-27 DZ DZ013399A patent/DZ3399A1/xx active
- 2001-06-27 PL PL393584A patent/PL393584A1/pl unknown
- 2001-06-27 CZ CZ20024224A patent/CZ20024224A3/cs not_active IP Right Cessation
- 2001-06-27 PE PE2001000629A patent/PE20020126A1/es not_active Application Discontinuation
- 2001-06-27 UA UA20021210397A patent/UA76952C2/uk unknown
- 2001-06-27 EP EP10178449A patent/EP2279748A1/en not_active Withdrawn
- 2001-06-27 KR KR1020077019832A patent/KR20070091698A/ko not_active Application Discontinuation
- 2001-06-27 EA EA200201240A patent/EA006313B1/ru not_active IP Right Cessation
- 2001-06-27 WO PCT/EP2001/007288 patent/WO2002000249A2/en active IP Right Grant
- 2001-06-27 CA CA2412497A patent/CA2412497C/en not_active Expired - Lifetime
- 2001-06-27 US US10/312,090 patent/US20030180316A1/en not_active Abandoned
-
2002
- 2002-12-17 IL IL153506A patent/IL153506A/en active IP Right Grant
- 2002-12-20 NO NO20026175A patent/NO332495B1/no not_active IP Right Cessation
- 2002-12-26 MA MA26980A patent/MA25824A1/fr unknown
- 2002-12-28 BG BG107422A patent/BG66238B1/bg active Active
-
2003
- 2003-08-27 HK HK03106153.7A patent/HK1055244A1/xx not_active IP Right Cessation
-
2009
- 2009-11-06 BG BG10110518A patent/BG66249B1/bg active Active
-
2010
- 2010-03-15 JP JP2010057779A patent/JP5346308B2/ja not_active Expired - Lifetime
-
2012
- 2012-01-30 CY CY20121100103T patent/CY1112280T1/el unknown
- 2012-04-04 US US13/439,829 patent/US9233151B2/en not_active Expired - Fee Related
- 2012-06-15 CY CY20121100549T patent/CY1112915T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY26801A1 (es) | Composición de vacuna | |
ATE480257T1 (de) | Kombinationsvakzine mit niedriger dosis eines hib-konjugats | |
NO20015073D0 (no) | Vaksiner | |
RU2012116119A (ru) | Множественная вакцинация, включающая менингококки серогруппы с | |
EA200801344A1 (ru) | Пневмококковая полисахаридная конъюгатная вакцина | |
DK1835939T3 (da) | Meningokokkonjugatvaccination | |
DE69527202D1 (de) | Proteinartige adjuvantien | |
LU91596I2 (fr) | Combinaison d'anatoxine diphtérique, d'anatoxine tétanique,d'antoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine, de virus poliomyélitique inactivé type 1, type 2 et type 3 et de polyoside capsulaire d'haemophilus influenzae type b (Infanrix - IPV/Hib) | |
RU2003101497A (ru) | Способ профилактики акдс-вакциной на крайнем севере |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
110 | Patent granted |
Effective date: 20140911 |
|
VENC | Patent expired |
Effective date: 20210627 |